Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544641 | 0.79 | FABP4 (0.52) | BRD9KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL23413323 | 0.78 | DAO (0.45) | AKT1KDM4ELCKHPGDATR | |
| SCHEMBL15302205 | 0.77 | CA1 (0.43) | AKT1LCKHTTMEN1KMT2A | |
| SCHEMBL30590406 | 0.75 | MAPT (0.43) | AKT1KDM4ELCKHPGDHTT | |
| SCHEMBL29546918 | 0.75 | ATR (0.42) | AKT1LCKATR | |
| SCHEMBL9099871 | 0.74 | KMT2A (0.67) | KDM4EALDH1A1HPGDHTTMEN1 | |
| SCHEMBL3494989 | 0.74 | NPC1 (0.70) | KDM4EALDH1A1HPGDLMNANPC1 | |
| SCHEMBL15627435 | 0.73 | LCK (0.48) | BRD9KDM4ELCKALDH1A1HPGD | |
| SCHEMBL30590411 | 0.73 | TRPA1 (0.38) | KDM4ELCKALDH1A1MEN1LMNA | |
| SCHEMBL28444082 | 0.73 | CHRM3 (0.52) | BRD9KDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20100256115-A1 | INHIBITORS OF IAP | COHEN FREDERICK | 2010-10-07 | — | — | US | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| CN-101035802-A | Inhibitors of IAP | GENENTECH INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778718-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014361-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | AKT1 2162/4885BRD9 2894/4885KDM4E 2792/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | AKT1 1298/4885BRD9 2073/4885KDM4E 2538/4885 |
| US-20120202750-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | AKT1 1298/4885BRD9 2073/4885KDM4E 2538/4885 |
| US-20100256115-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | AKT1 1298/4885BRD9 2073/4885KDM4E 2538/4885 |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | BIRC5, BIRC2, XIAP | AKT1 2431/4885BRD9 1187/4885KDM4E 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.